Finerenone for Prevention of First-Detected AF Across the Cardio-Kidney-Metabolic Spectrum: Insights From the FINE-HEART Pooled Analysis.

COI Statement

Funding Support and Author Disclosures Dr Piccini was supported by R01AG074185 from the National Institute on Aging. Dr Piccini has received grants for clinical research from Abbott, the American Heart Association, Boston Scientific, iRhythm, and Philips; has served as a consultant for Abbott, SymKardia, Bayer, Medtronic, Milestone Pharmaceuticals, Novartis, Sanofi, Philips, and UpToDate; and has served on data safety and monitoring boards for Kardium and Conformal. Dr DeVore has received research funding through his institution from Biofourmis, Bodyport, Cytokinetics, American Regent, the National Institutes of Health and National Heart, Lung, and Blood Institute, Natera, Novartis, Story Health, and Ventricle Health; and has served as a consultant and/or received honoraria from Abiomed, Bodyport, Cardionomic, LivaNova, Myovant, Natera, Novo Nordisk, and Zoll. Dr Fudim has reported that he has no relationships relevant to the contents of this paper to disclose.